/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

Biofrontera Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$0.78 -0.0202(-2.02%) BFRI at 04 Dec 2025 04:26 PM Drug Manufacturers - Specialty & Generic
Lowest Today 0.767
Highest Today 0.8299
Today’s Open 0.78375
Prev. Close 0.81
52 Week High 1.25
52 Week Low 0.54
Day’s Range: Low 0.767 High 0.8299
52-Week Range: Low 0.54 High 1.25
1 day return -
1 Week return -0.18
1 month return -24.65
3 month return -6.12
6 month return +25.57
1 year return -21.67
3 year return -96.26
5 year return -
10 year return -

Institutional Holdings

Rosalind Advisors, Inc. 9.15

AIGH Capital Management, LLC 9.13

Geode Capital Management, LLC 0.38

Fidelity Extended Market Index 0.30

Virtu Financial LLC 0.20

Vanguard Institutional Extnd Mkt Idx Tr 0.14

HRT FINANCIAL LLC 0.11

XTX Topco Ltd 0.11

Fidelity Series Total Market Index 0.07

BlackRock Inc 0.04

Spartan Total Market Index Pool G 0.02

UBS Group AG 0.01

NT Ext Equity Mkt Idx Fd - NL 0.01

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.00

Fidelity Total Market Index 0.00

Northern Trust Extended Eq Market Idx 0.00

NT Ext Equity Mkt Idx Fd - L 0.00

SBI Securities Co Ltd 0.00

Spartan Extended Market Index Pool F 0.00

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.00

NT Ext Eq Mkt Indx Fd DC Lend T3 0.00

State St US Extended Mkt Indx NL Cl C 0.00

Bank of America Corp 0.00

State St US Ttl Mkt Indx NL Cl A 0.00

SSgA U.S. Total Market Index Strategy 0.00

Blackstone Alternative Multi-Strategy I 0.00

Extended Equity Market Fund K 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

Advisor Group Holdings, Inc. 0.00

Citadel Advisors Llc 0.00

Extended Equity Market Fund M 0.00

Goldman Sachs Group Inc 0.00

JPMorgan Chase & Co 0.00

Millennium Management LLC 0.00

Morgan Stanley - Brokerage Accounts 0.00

Scotia Capital Inc 0.00

Tower Research Capital LLC 0.00

TWO SIGMA SECURITIES, LLC 0.00

Market Status

Strong Buy: 1

Buy: 1

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 9.44 M

PB Ratio 0.6503

PE Ratio 0.0

Enterprise Value 10.96 M

Total Assets 22.10 M

Volume 440274

Company Financials

Annual Revenue FY23:33619000 33.6M, FY22:28674000 28.7M, FY21:24100000 24.1M, FY20:18849000 18.8M, FY19:26181000 26.2M

Annual Profit FY23:16287000 16.3M, FY22:13489000 13.5M, FY21:11358000 11.4M, FY20:9783000 9.8M, FY19:13773000 13.8M

Annual Net worth FY23:-26442000 -26.4M, FY22:-640000 -0.6M, FY21:-37713000 -37.7M, FY20:-10987000 -11.0M, FY19:-10982000 -11.0M

Quarterly Revenue Q3/2025:6988000 7.0M, Q2/2025:9030000 9.0M, Q1/2025:8588000 8.6M, Q3/2024:9012000 9.0M, Q2/2024:7839000 7.8M

Quarterly Profit Q3/2025:5066000 5.1M, Q2/2025:6650000 6.7M, Q1/2025:5513000 5.5M, Q3/2024:4135000 4.1M, Q2/2024:3497000 3.5M

Quarterly Net worth Q3/2025:-6649000 -6.6M, Q2/2025:-5324000 -5.3M, Q1/2025:-4203000 -4.2M, Q3/2024:-5669000 -5.7M, Q2/2024:-257000 -0.3M

Fund house & investment objective

Company Information Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a common skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Organisation Drug Manufacturers - Specialty & Generic

Employees 92

Industry Drug Manufacturers - Specialty & Generic

CEO Dr. Hermann Luebbert Ph.D.

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow